ASP8825 + Placebo

Phase 2Terminated

2 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diabetic Neuropathies

Conditions

Diabetic Neuropathies

Trial Timeline

Jul 1, 2007 → Nov 1, 2008

NCT ID

NCT00508430

About ASP8825 + Placebo

ASP8825 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Diabetic Neuropathies. The current trial status is terminated. This product is registered under clinical trial identifier NCT00508430. Target conditions include Diabetic Neuropathies.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Neuropathies were approved

Approved (20) Terminated (3) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅duloxetine hydrochlorideEli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00530530	Phase 2	Completed	Sep 1, 2007	Jan 1, 2009	Restless Legs Syndrome
NCT00508430	Phase 2	Terminated	Jul 1, 2007	Nov 1, 2008	Diabetic Neuropathies

Competing Products

20 competing products in Diabetic Neuropathies

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	25
CHF6467 active	Comac Medical	Phase 1/2	22
Ruboxistaurin mesylate	Eli Lilly	Phase 3	40
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	29
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	23
Baricitinib + Placebo	Eli Lilly	Phase 2	35
LY3857210 + Placebo	Eli Lilly	Phase 2	35
UBX1325	Unity Biotechnology	Phase 2	25
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	25
UBX1325	Unity Biotechnology	Phase 1	19
CT-P42 + Eylea	Celltrion	Phase 3	40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22